JP2023508740A5 - - Google Patents
Info
- Publication number
- JP2023508740A5 JP2023508740A5 JP2022540754A JP2022540754A JP2023508740A5 JP 2023508740 A5 JP2023508740 A5 JP 2023508740A5 JP 2022540754 A JP2022540754 A JP 2022540754A JP 2022540754 A JP2022540754 A JP 2022540754A JP 2023508740 A5 JP2023508740 A5 JP 2023508740A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- immune effector
- cells
- modified
- immunoeffector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010002929.3 | 2020-01-02 | ||
| CN202010002929 | 2020-01-02 | ||
| PCT/CN2020/140799 WO2021136263A1 (zh) | 2020-01-02 | 2020-12-29 | 一种经修饰的免疫效应细胞及其制备方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508740A JP2023508740A (ja) | 2023-03-03 |
| JP2023508740A5 true JP2023508740A5 (https=) | 2025-03-06 |
| JP7670358B2 JP7670358B2 (ja) | 2025-04-30 |
Family
ID=76559305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540754A Active JP7670358B2 (ja) | 2020-01-02 | 2020-12-29 | 修飾された免疫エフェクター細胞及びその調製方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220193135A1 (https=) |
| EP (1) | EP4086342A4 (https=) |
| JP (1) | JP7670358B2 (https=) |
| KR (1) | KR20220124197A (https=) |
| CN (2) | CN115003802B (https=) |
| AU (1) | AU2020418199B2 (https=) |
| CA (1) | CA3163304A1 (https=) |
| WO (1) | WO2021136263A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111393533B (zh) * | 2020-04-16 | 2021-05-11 | 成都仕康美生物科技有限公司 | 靶向HLA-A的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途 |
| AU2021386366A1 (en) * | 2020-11-24 | 2023-06-29 | A2 Biotherapeutics, Inc. | Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity |
| WO2023274387A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
| EP4365203A4 (en) | 2021-07-01 | 2025-09-24 | Ningbo T Maximum Biopharmaceuticals Co Ltd | ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND ITS APPLICATION |
| WO2023274386A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向egfr的通用型car-t细胞及其制备方法 |
| AU2022331424A1 (en) * | 2021-08-16 | 2024-02-22 | Beam Therapeutics Inc. | Persistent allogeneic modified immune cells and methods of use thereof |
| CN118742571A (zh) * | 2022-02-09 | 2024-10-01 | 恺兴生命科技(上海)有限公司 | 用于细胞免疫学的组合物和方法 |
| TW202340457A (zh) * | 2022-02-28 | 2023-10-16 | 美商凱特製藥公司 | 同種異體治療細胞 |
| CN114878822A (zh) * | 2022-05-11 | 2022-08-09 | 苏州逻晟生物医药有限公司 | 一种抗cd137单克隆抗体的生物活性测定方法 |
| CN117986362A (zh) * | 2022-11-04 | 2024-05-07 | 茂行制药(苏州)有限公司 | 靶向b7h3的通用型car-t细胞及其制备方法和应用 |
| CN118922551A (zh) * | 2023-01-30 | 2024-11-08 | 南京北恒生物科技有限公司 | 用于CRISPR-Cas基因编辑系统的方法及组合物 |
| CN118325904B (zh) * | 2024-06-17 | 2024-10-01 | 天海元祺生物科技(天津)有限公司 | 高度靶向人类HLA-A基因的sgRNA、其组合物及应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050227940A1 (en) * | 2004-01-23 | 2005-10-13 | City Of Hope | Amplifying interfering RNA (RNAi) expression and effects |
| US10391126B2 (en) * | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| AR097648A1 (es) | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
| AU2014364593A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody |
| WO2015161276A2 (en) * | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| US20170335331A1 (en) * | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| WO2017093969A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| US20190136230A1 (en) * | 2016-05-06 | 2019-05-09 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
| EP3475706B1 (en) * | 2016-06-27 | 2021-08-11 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
| MX2019013514A (es) * | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US11512287B2 (en) * | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
| CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| CN109456943A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| EP3686275A4 (en) * | 2017-09-18 | 2021-09-29 | Edigene Inc. | GENE EDITING LYMPHOCYTE T AND RELATED USE |
| CN107630006B (zh) * | 2017-09-30 | 2020-09-11 | 山东兴瑞生物科技有限公司 | 一种制备tcr与hla双基因敲除的t细胞的方法 |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| CN109750035B (zh) * | 2017-11-02 | 2020-06-05 | 上海邦耀生物科技有限公司 | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA |
| WO2019160077A1 (ja) * | 2018-02-16 | 2019-08-22 | 国立大学法人京都大学 | 低抗原性細胞の製造方法 |
-
2020
- 2020-12-29 AU AU2020418199A patent/AU2020418199B2/en active Active
- 2020-12-29 CN CN202080090688.0A patent/CN115003802B/zh active Active
- 2020-12-29 JP JP2022540754A patent/JP7670358B2/ja active Active
- 2020-12-29 KR KR1020227026014A patent/KR20220124197A/ko active Pending
- 2020-12-29 CN CN202011605256.7A patent/CN113061580B/zh active Active
- 2020-12-29 EP EP20911252.3A patent/EP4086342A4/en active Pending
- 2020-12-29 WO PCT/CN2020/140799 patent/WO2021136263A1/zh not_active Ceased
- 2020-12-29 CA CA3163304A patent/CA3163304A1/en active Pending
-
2021
- 2021-12-28 US US17/563,804 patent/US20220193135A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508740A5 (https=) | ||
| US12344651B2 (en) | CD19 and CD22 chimeric antigen receptors and uses thereof | |
| US20250382621A1 (en) | Immune effector cell therapies with enhanced efficacy | |
| JP7295283B2 (ja) | Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法 | |
| US12447213B2 (en) | Modulation of novel immune checkpoint targets | |
| US11446398B2 (en) | Regulated biocircuit systems | |
| JP7395483B2 (ja) | ｍＲＮＡの細胞内送達のためのペプチドおよびナノ粒子 | |
| US12241053B2 (en) | Modulation of novel immune checkpoint targets | |
| KR102717188B1 (ko) | 암의 치료를 위한 키메라 항원 수용체 | |
| CN114375296A (zh) | 核酸多肽组合物及其用途 | |
| JP2021522820A (ja) | 癌を治療するための方法及び組成物 | |
| JP7471289B2 (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| CN107531790A (zh) | 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用 | |
| AU2018240295A1 (en) | Biomarkers and car T cell therapies with enhanced efficacy | |
| JP2020506189A (ja) | Ｒｎａ癌ワクチン | |
| JP2024097924A (ja) | 抗ｐｔｋ７免疫細胞癌療法 | |
| KR20210143804A (ko) | 혈액암 및 고형 종양암의 치료를 위한 키메라 항원 수용체 변형된 t 세포 (car-t) | |
| CN111629715A (zh) | 通过调节细胞活化状态改变体内免疫细胞的炎症状态 | |
| JP7682104B2 (ja) | 非小細胞肺がんを処置するための方法および組成物 | |
| JP2024506550A (ja) | 治療剤及び診断剤並びにその使用 | |
| JP2022513412A5 (https=) | ||
| US20250352651A1 (en) | Compositions comprising pln-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy | |
| JP2024527539A5 (https=) | ||
| CN119638851A (zh) | 一种用于桥接造血干细胞移植的多靶点嵌合抗原受体及其应用 | |
| TW202307210A (zh) | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |